Clinical trial · Observational
Prostate Cancer - Comparative Outcomes of New Conceptual Paradigms for Treatment
NCT04890314CI-TRIAL-00090051PC-CONCEPTcompletedResults postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will use a population-based cohort design to study men with newly diagnosed low- and intermediate-risk prostate cancer at high-volume centers in Southern California (SCa) and New York State (NYS). Complications of contemporary treatments for prostate cancer and quality of life outcomes, such as general health, urinary, sexual, and bowel function, cancer anxiety, and treatment regret will be compared and tracked over the course of this study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patient-reported questionnaire | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- Active Surveillance (AS)
- description
- Doctor will monitor the patient without directly treating the cancer.
- interventionNames
- Other: Patient-reported questionnaire
- label
- Stereotactic Body Radiation Therapy (SBRT)
- description
- Radiation treatment of prostate cancer requiring less than 2 weeks of treatment.
- interventionNames
- Other: Patient-reported questionnaire
- label
- Intensity-Modulated Radiation Therapy (IMRT)
- description
- Radiation treatment of prostate cancer requiring more than 2 weeks of treatment.
- interventionNames
- Other: Patient-reported questionnaire
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically-confirmed clinically localized prostate adenocarcinoma with National Comprehensive Cancer Network (NCCN) low (T1-T2a, Gleason 6, Grade Group 1, PSA \<10 ng/mL) or intermediate risk (T2b-T2c or, Gleason 7, Grade Group 2 or 3 or PSA 10-20 ng/mL)72 at one of the selected hospitals in SCa and NYS * Diagnosis date during the 18 month recruitment window * Able to read/speak English or Spanish * Agree to participate by completing the baseline questionnaire Exclusion Criteria: * Clinically metastatic disease or high-risk PCa (T3a-T4, Gleason Grade Group 4 or 5 or PSA \>20 ng/mL * Unable to read/speak English or Spanish * Unwilling or unable to give informed consent.
References
Publications (0)
Data not yet available
No reference posted for this study.